ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Hippocampal tau distribution in primary age-related tauopathy: The Vantaa 85+ Study.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Proteomic comparison of hippocampal neurofibrillary tangles in PART, intermediate Alzheimer's disease and advanced Alzheimer's disease.Acta neuropathologica · 2026Article
- Amyloid plaques associated with shift in patterns of hippocampal tau pathology in middle age.Journal of Alzheimer's disease : JAD · 2026Article
- Neocortical tau burden determines the degree of cognitive impairment in individuals with Braak stage V neurofibrillary degeneration.Acta neuropathologica · 2026Article
- Cellular state heterogeneity underlying sex differences in Alzheimer's disease based on single-cell transcriptome.Alzheimer's research & therapy · 2026Article
- Proteomic remodelling of the neurofibrillary tangle from "PART" to advanced Alzheimer's disease.Research square · 2026Article
- Longitudinal assessment of cognitive decline and resilience in high-level Alzheimer disease neuropathologic change.Alzheimer's research & therapy · 2025Article
- Primary age-related tauopathy.Acta neuropathologica · 2025Review
- Hippocampal tau distribution in primary age-related tauopathy: The Vantaa 85+ Study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Brain banking for research: can we achieve efficient banking?Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionIn contrast to Alzheimer's disease (AD), in which initial neurofibrillary tangles (NFT) are mainly limited to the (trans)entorhinal region (EC) and CA1/prosubiculum, primary age-related tauopathy (PART) has been suggested to exhibit an early predisposition to NFTs in the hippocampal CA2 subregion.
methodsWe created an artificial intelligence model that recognizes and quantifies NFTs of three different maturity levels in different hippocampal subfields. This model was applied to a population-based Vantaa 85+ cohort, including hippocampal tau-immunostained sections from 210 individuals aged ≥ 85 years.
resultsEC and CA1, but not CA2, had significantly higher NFT density in moderate AD compared to PART. CA2/CA1 and CA2/EC NFT ratios were inversely associated with amyloid beta (Aβ) deposition in PART versus AD. The maturation process was exacerbated by Aβ in AD versus PART. DISCUSSION: Compared to AD, a CA2 conspicuous pattern of hippocampal NFTs was more common in, but not exclusive to, PART. HIGHLIGHTS: Neurofibrillary tangles (NFTs) of varying maturity were studied by a new kind of artificial intelligence model in the oldest-old. Hippocampal NFT distribution differed between primary age-related tauopathy (PART) and Alzheimer's disease (AD). PART more often showed prominent NFT pathology in CA2 compared to AD. In PART, the NFT maturation process stood out in CA2 compared to other subfields. The NFT maturation process was aggravated by amyloid beta in AD compared to PART.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.